Icon (NASDAQ:ICLR) released its earnings results on Thursday. The medical research company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02, Morningstar.com reports. Icon had a return on equity of 28.42% and a net margin of 16.37%. The company had revenue of $455.10 million for the quarter, compared to the consensus estimate of $455.66 million. During the same quarter last year, the business posted $1.33 EPS. Icon’s quarterly revenue was up 4.6% compared to the same quarter last year. Icon updated its FY18 guidance to $5.89-6.09 EPS.

Shares of Icon (ICLR) opened at $110.19 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $5,922.06, a P/E ratio of 21.35, a PEG ratio of 1.54 and a beta of 0.48. Icon has a 1 year low of $76.46 and a 1 year high of $124.48.

ICLR has been the topic of a number of research analyst reports. SunTrust Banks reaffirmed a “buy” rating and set a $133.00 target price on shares of Icon in a report on Monday, January 22nd. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $132.00 price target on the stock in a research report on Tuesday, January 9th. KeyCorp reiterated a “buy” rating and set a $130.00 price target on shares of Icon in a research report on Thursday, January 11th. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Finally, Barclays increased their price target on Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $124.55.

Several institutional investors have recently made changes to their positions in the company. GRATRY & Co LLC increased its position in Icon by 5.1% in the 3rd quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock valued at $3,433,000 after acquiring an additional 1,474 shares during the period. Insight Capital Research & Management Inc. acquired a new stake in Icon in the 3rd quarter valued at approximately $1,359,000. BT Investment Management Ltd acquired a new stake in Icon in the 3rd quarter valued at approximately $325,000. JPMorgan Chase & Co. increased its position in Icon by 11.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 42,043 shares of the medical research company’s stock valued at $4,697,000 after acquiring an additional 4,320 shares during the period. Finally, NorthCoast Asset Management LLC increased its position in Icon by 23.4% in the 3rd quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock valued at $2,052,000 after acquiring an additional 3,419 shares during the period. Institutional investors and hedge funds own 89.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://theolympiareport.com/2018/02/15/icon-iclr-announces-earnings-results.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.